Physician profile
Soumen Samaddar
NPI 1790004752
$3,900.10
in general payments reported to CMS, 2019-2025
33 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $340 · 2021: $405 · 2022: $773 · 2023: $724 · 2024: $885 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,178 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.26 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $579.96 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $523.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $500.80 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $469.58 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $354.70 | 2022-2024 | Caplyta |
| Lilly USA, LLC | $147.51 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Abbott Laboratories | $140.55 | 2021-2024 | Freestyle Libre 3 |
| Medtronic, INC. | $115.06 | 2024 | Interstim |
| Merck Sharp & Dohme LLC | $114.87 | 2019-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Biohaven Pharmaceutical Holding Company LTD. | $101.26 | 2022 | |
| Amgen INC. | $95.58 | 2023-2025 | Repatha, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $81.19 | 2019-2024 | Austedo Xr |
| Sanofi Pasteur INC. | $72.99 | 2019-2022 | |
| Glaxosmithkline, LLC. | $72.95 | 2023-2024 | Shingrix, Arexvy |
| Exact Sciences Corporation | $50.70 | 2025 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $49.27 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $47.78 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $44.79 | 2021 | |
| Allergan, INC. | $40.90 | 2020 | |
| Kvk-Tech, INC. | $38.15 | 2025 | |
| Lundbeck LLC | $29.98 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $28.95 | 2022-2025 | |
| Exeltis, USA INC. | $28.08 | 2021 | |
| Philips North America LLC | $23.87 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.43 | 2022 | |
| Boston Scientific Corporation | $20.07 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.76 | 2025 | Jardiance |
| Strongbridge US INC. | $15.47 | 2019 | |
| Amarin Pharma, INC. | $14.82 | 2020 | |
| Genentech USA, INC. | $14.38 | 2020 | |
| Axsome Therapeutics, INC. | $14.14 | 2025 | Symbravo |
| Gilead Sciences, INC. | $13.93 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.78 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soumen Samaddar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.